Michael (Ted) Burczynski, Ph.D.

Michael (Ransom) Burczynski received his Ph.D. in Pharmacology and Toxicology from the University of Pennsylvania, and was awarded with an AACR young investigator award during his thesis research. He conducted seminal research in the nascent field of toxicogenomics during his postdoctoral fellowship at Johnson and Johnson.  He worked at Wyeth Pharmaceuticals in Discovery until 2005, and was relocated to become the founding member of the Department of Clinical Translational Medicine where he created and ultimately led the Wyeth Biomarker Laboratories, a department comprised of various laboratories responsible for pharmacogenomics, immunoassays, flow cytometry and mass-spectrometry biomarker assay development and validation.  He joined Roche in 2009 as the Global Head of Genomics and Genetics and led groups in the U.S. and E.U. to support Translational Research Sciences in pharmaceutical research and early development (pRED).  He has been at BMS since 2011 where he serves as Executive Director and Head of Biomarker Technologies in the Department of Early Clinical Translational Research.   He is the chair of the BMS Biomarker Technology Matrix and sits on various external editorial boards and advisory committees.  He has published numerous research articles in genomics, biomarker research and translational medicine, and has edited two textbooks: An Introduction to Toxicogenomics (CRC Press)and Surrogate Tissue Analysis: An Introduction to Genomic, Proteomic and Metabolomic Methods (Taylor and Francis).  Since 2006 he has been on the adjunct faculty in the Department of Pharmacology at the University of Pennsylvania School of Medicine.   He recently authored a biomedical thriller entitled The Ripper Gene, coming from Tor-Forge books in early 2015.